Janina Blattner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Janina Blattner has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Berna Cennet Özdemir
Department of Medical Oncology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland
1 shared publication - Katrin Gobat
Swiss Group for Clinical Cancer Research (SAKK), 3008 Bern, Switzerland
1 shared publication - Marie-Noelle Kronig
Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland
1 shared publication - Michèle Hoffmann
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
1 shared publication - Thomas Pabst
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
1 shared publication - Xenia Darphin
Department of Hematology, Spital Limmattal, 8952 Schlieren, Switzerland
1 shared publication
Latest Publications
- Open Access
- 13 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6457
Sex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis
Background: Acute myeloid leukemia (AML) is a challenging disease due to its aggressive nature and interindividual variability in treatment response. While sex differences in AML incidence and outcomes have been reported, the impact of sex on treatment-related toxicity remains underexplored. Methods: We retrospectively analyzed patients who received intensive chemotherapy for de novo or secondary AML at a single academic hospital between 1 January 2017 and 30 November 2021. A total of 65 patients (62% males) were included, with similar risk categories across sexes. Results: Although adverse event rates were similar, females had significantly higher rates of neutropenic colitis (100% vs. 80%, p = 0.019) after the first induction cycle. Hematological recovery after the second cycle was faster in males for neutrophils (21 vs. 28 days, p = 0.025) and thrombocytes (27 vs. 37 days, p = 0.02). Hospitalization duration was also significantly longer for females (26 days vs. 24 days, p = 0.039). The median overall survival did not differ by sex, but was significantly longer for those receiving two cycles vs. one cycle (0.5 years vs. NR) and for those <60 years old (6.1 vs. 1.0 years). Conclusions: These findings suggest sex-related differences in treatment toxicity and hospital stay length. Larger studies are needed to better understand the impact of sex on AML outcomes.
- 13 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6457
Open AccessSex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis
Background: Acute myeloid leukemia (AML) is a challenging disease due to its aggressive nature and interindividual variability in treatment response. While sex differences in AML incidence and outcomes have been reported, the impact of sex on treatment-related toxicity remains underexplored. Methods: We retrospectively analyzed patients who received intensive chemotherapy for de novo or secondary AML at a single academic hospital between 1 January 2017 and 30 November 2021. A total of 65 patients (62% males) were included, with similar risk categories across sexes. Results: Although adverse event rates were similar, females had significantly higher rates of neutropenic colitis (100% vs. 80%, p = 0.019) after the first induction cycle. Hematological recovery after the second cycle was faster in males for neutrophils (21 vs. 28 days, p = 0.025) and thrombocytes (27 vs. 37 days, p = 0.02). Hospitalization duration was also significantly longer for females (26 days vs. 24 days, p = 0.039). The median overall survival did not differ by sex, but was significantly longer for those receiving two cycles vs. one cycle (0.5 years vs. NR) and for those <60 years old (6.1 vs. 1.0 years). Conclusions: These findings suggest sex-related differences in treatment toxicity and hospital stay length. Larger studies are needed to better understand the impact of sex on AML outcomes.